EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review

Yukari Bando, Junya Furukawa, Takuto Hara, Yasuyoshi Okamura, Tomoaki Terakawa, Yuzo Nakano, Masato Fujisawa

Urologia Internationalis · 2023 · 107 (3) · 321-326

DOI: 10.1159/000528447 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Urologia Internationalis, online erschienen am 02.02.2023. Verfasst von Yukari Bando und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Failure, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsKidney Failure, ChronicMaleHumansAgedAxitinibRetrospective StudiesRenal DialysisAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AvelumabAxitinibCombination therapyEnd-stage renal diseaseHemodialysis

Substanzen

AxitinibavelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Zitieren

APA

Bando, Y., Furukawa, J., Hara, T., Okamura, Y., Terakawa, T., Nakano, Y., & Fujisawa, M. (2023). Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review. Urologia Internationalis, 107(3), 321-326. https://doi.org/10.1159/000528447

Vancouver

Bando Y, Furukawa J, Hara T, Okamura Y, Terakawa T, Nakano Y, et al. Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review. Urologia Internationalis. 2023;107(3):321-326. doi:10.1159/000528447

BibTeX
@article{Bando2023,
  author = {Bando, Yukari and Furukawa, Junya and Hara, Takuto and Okamura, Yasuyoshi and Terakawa, Tomoaki and Nakano, Yuzo and Fujisawa, Masato},
  title = {Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review},
  journal = {Urologia Internationalis},
  year = {2023},
  volume = {107},
  number = {3},
  pages = {321--326},
  doi = {10.1159/000528447}
}
Kostenlos starten →